Mason B H, Holdaway I M, Benton N M, Benson-Cooper D M, Hadden W E, Kay R G
Department of Surgery, University of Auckland School of Medicine.
N Z Med J. 1993 Feb 10;106(949):23-5.
To determine the efficacy and extent of screening mammography for detection of contralateral breast cancer in a cohort of women with previous unilateral mammary carcinoma, and to assess the effect of endocrine therapy on the risk of developing cancer in the contralateral breast.
Women with previous breast cancer eligible for mammography were identified from the Auckland breast cancer data file and the extent and outcome of mammographic screening determined by questionnaire and survey of mammography reports. The extent of adjuvant hormonal therapy and development of contralateral breast cancer was ascertained from the ABCDF records.
Of 703 eligible subjects, 59% had undergone screening mammography with a cancer detection rate of 17 per 1000 mammograms and a benign to malignant ratio was 1.7 to 1. Contralateral breast cancer developed in 2.9% of 1980 women with previous unilateral mammary tumours who did not receive endocrine therapy with 1.1% of 374 women who were given adjuvant hormonal treatment (p = 0.04).
The efficacy of mammography in those screened was comparable to major overseas screening programs, but the proportion of women undergoing mammography in this high risk group was relatively low suggesting a need for greater promotion of mammography in Auckland. The use of adjuvant endocrine therapy significantly reduced the rate of development of contralateral breast tumours supporting the current development of formal trials of chemoprevention of breast cancer in women at high risk groups of the disorder.
确定在既往有单侧乳腺癌的女性队列中,乳腺钼靶筛查对检测对侧乳腺癌的有效性和范围,并评估内分泌治疗对侧乳腺癌发生风险的影响。
从奥克兰乳腺癌数据文件中识别出符合乳腺钼靶检查条件的既往乳腺癌女性,通过问卷调查和乳腺钼靶检查报告调查确定钼靶筛查的范围和结果。从ABCDF记录中确定辅助激素治疗的范围和对侧乳腺癌的发生情况。
在703名符合条件的受试者中,59%接受了乳腺钼靶筛查,癌症检出率为每1000次钼靶检查17例,良性与恶性比例为1.7比1。在1980名既往有单侧乳腺肿瘤且未接受内分泌治疗的女性中,2.9%发生了对侧乳腺癌,在374名接受辅助激素治疗的女性中,这一比例为1.1%(p = 0.04)。
钼靶筛查对接受筛查者的有效性与国外主要筛查项目相当,但在这一高风险组中接受钼靶检查的女性比例相对较低,这表明在奥克兰需要加大对钼靶检查的推广力度。辅助内分泌治疗的使用显著降低了对侧乳腺肿瘤的发生率,这支持了目前针对该疾病高风险组女性开展乳腺癌化学预防正式试验的进展。